Hims & Hers Health, Inc. Q3 2025 Earnings Recap

HIMS Q3 2025 November 4, 2025

Get alerts when HIMS reports next quarter

Hims & Hers reported a robust Q3 2025, achieving nearly 50% year-over-year revenue growth driven by a 50% increase in subscribers using personalized health solutions, bolstered by strategic partnerships and innovations.

Earnings Per Share Miss

$0.06 vs $0.09 est.

-33.3% surprise

Revenue Miss

598976000 vs 618054540 est.

-3.1% surprise

Market Reaction

1-Day -3.6%

5-Day -7.57%

30-Day -10.23%

See HIMS alongside your other holdings

Add to your portfolio — free

Key Takeaways

Subscribers utilizing personalized care solutions surged 50% year-over-year, underpinning revenue growth.
Strategic partnerships with Novo Nordisk and Marius Pharmaceuticals aim to expand access to innovative treatments, including Wegovy.
The company made a significant investment in GRAIL, enhancing its offerings in multi-cancer early detection.
A strategic reduction in GLP-1 treatment prices by up to 20% aims to broaden care accessibility.
Ongoing verticalization of compounding operations is expected to improve efficiency and quality in service delivery.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit HIMS on AllInvestView.

Next Q1 2026